In a major medical breakthrough, the NHS has approved Capivasertib for funding in England. Used in combination with hormone therapy, the drug has shown significant promise in clinical trials—shrinking tumours in nearly a quarter of advanced breast cancer patients. This approval brings new hope to thousands battling the disease.